MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1056/nejmoa1605085

Медицинская библиотека · The New England journal of medicine · 2016

Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia.

Maury Sébastien, Chevret Sylvie, Thomas Xavier, Heim Dominik, Leguay Thibaut, Huguet Françoise, Chevallier Patrice, Hunault Mathilde, Boissel Nicolas, Escoffre-Barbe Martine, Hess Urs, Vey Norbert, Pignon Jean-Michel, Braun Thorsten, Marolleau Jean-Pierre, Cahn Jean-Yves, Chalandon Yves, Lhéritier Véronique, Beldjord Kheira, Béné Marie C, Ifrah Norbert, Dombret Hervé, for GRAALL

СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Treatment with rituximab has improved the outcome for patients with non-Hodgkin's lymphoma. Patients with B-lineage acute lymphoblastic leukemia (ALL) may also have the CD20 antigen, which is targeted by rituximab. Although single-group studies suggest that adding rituximab to chemotherapy could improve the outcome in such patients, this hypothesis has not been tested in a randomized trial.

METHODS

We randomly assigned adults (18 to 59 years of age) with CD20-positive, Philadelphia chromosome (Ph)-negative ALL to receive chemotherapy with or without rituximab, with event-free survival as the primary end point. Rituximab was given during all treatment phases, for a total of 16 to 18 infusions.

RESULTS

From May 2006 through April 2014, a total of 209 patients were enrolled: 105 in the rituximab group and 104 in the control group. After a median follow-up of 30 months, event-free survival was longer in the rituximab group than in the control group (hazard ratio, 0.66; 95% confidence interval [CI], 0.45 to 0.98; P=0.04); the estimated 2-year event-free survival rates were 65% (95% CI, 56 to 75) and 52% (95% CI, 43 to 63), respectively. Treatment with rituximab remained associated with longer event-free survival in a multivariate analysis. The overall incidence rate of severe adverse events did not differ significantly between the two groups, but fewer allergic reactions to asparaginase were observed in the rituximab group.

CONCLUSIONS

Adding rituximab to the ALL chemotherapy protocol improved the outcome for younger adults with CD20-positive, Ph-negative ALL. (Funded by the Regional Clinical Research Office, Paris, and others; ClinicalTrials.gov number, NCT00327678 .).

Для цитирования: Maury Sébastien, Chevret Sylvie, Thomas Xavier, Heim Dominik, Leguay Thibaut, Huguet Françoise, Chevallier Patrice, Hunault Mathilde, Boissel Nicolas, Escoffre-Barbe Martine, Hess Urs, Vey Norbert, Pignon Jean-Michel, Braun Thorsten, Marolleau Jean-Pierre, Cahn Jean-Yves, Chalandon Yves, Lhéritier Véronique, Beldjord Kheira, Béné Marie C, Ifrah Norbert, Dombret Hervé, for GRAALL. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia.. The New England journal of medicine. 2016. DOI: 10.1056/nejmoa1605085.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.